Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Indinavir Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 18/20 | 0.99 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.99 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.99 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.99 |
| ▸ | TACR2 | P21452 | 1/20 | 0.99 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.99 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.99 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.99 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.95 |
| ▸ | LMNA | P02545 | 1/20 | 0.95 |
| ▸ | CYP2D6 | P10635 | 13/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indinavir Anhydrous SCHEMBL1176257 | 1.00 | CYP3A4 (0.99) | CYP3A4ABCC3ABCB11ABCB1TACR2 | |
| Indinavir Anhydrous SCHEMBL7752012 | 1.00 | CYP3A4 (0.99) | CYP3A4ABCC3ABCB11ABCB1TACR2 | |
| Indinavir Anhydrous SCHEMBL19760130 | 1.00 | CYP3A4 (0.99) | CYP3A4ABCC3ABCB11ABCB1TACR2 | |
| Indinavir Anhydrous SCHEMBL13039789 | 1.00 | CYP3A4 (0.99) | CYP3A4ABCC3ABCB11ABCB1TACR2 | |
| Indinavir Anhydrous SCHEMBL20099152 | 1.00 | CYP3A4 (0.99) | CYP3A4ABCC3ABCB11ABCB1TACR2 | |
| Indinavir Anhydrous SCHEMBL17787450 | 1.00 | CYP3A4 (0.99) | CYP3A4ABCC3ABCB11ABCB1TACR2 | |
| Indinavir Anhydrous SCHEMBL6908581 | 1.00 | CYP3A4 (0.99) | CYP3A4ABCC3ABCB11ABCB1TACR2 | |
| Indinavir Anhydrous SCHEMBL21683359 | 1.00 | CYP3A4 (0.99) | CYP3A4ABCC3ABCB11ABCB1TACR2 | |
| Indinavir Anhydrous SCHEMBL21578565 | 1.00 | CYP3A4 (0.99) | CYP3A4ABCC3ABCB11ABCB1TACR2 | |
| Indinavir Anhydrous SCHEMBL13575769 | 1.00 | CYP3A4 (0.99) | CYP3A4ABCC3ABCB11ABCB1TACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12564595-B2 | Prophylactic and therapeutic pharmaceutical agent for HIV infectious diseases characterized by comprising combination of integrase inhibitor and anti-HIV agent | SHIONOGI & CO., LTD. (JP) | 2026-03-03 | — | — | US | disclosed |
| EP-4667008-A2 | METHODS AND COMPOSITIONS FOR TREATING RNA VIRAL INFECTIONS | Model Medicines, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12083099-B2 | Methods of treating symptoms of coronavirus infection with viral protease inhibitors | Accencio LLC (US) | 2024-09-10 | — | — | US | disclosed |
| US-20240041828-A1 | Combination Therapeutics Comprising Nrf2 Agonists and Antivirals for Treating Viral Infections | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-02-08 | — | — | US | disclosed |
| US-20240041764-A1 | Sustained-Release Oral Fosamprenavir Formulation for Treatment of Reflux | N-ZYME BIOMEDICAL INC. (CA) | 2024-02-08 | — | — | US | disclosed |
| US-20230248712-A1 | METHODS AND COMPOSITIONS FOR TREATING RNA VIRAL INFECTIONS | MODEL MEDICINES, INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230113114-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION WITH VIRAL PROTEASE INHIBITORS | Accencio LLC | 2023-04-13 | — | — | US | disclosed |
| US-20230059640-A1 | PROPHYLACTIC AND THERAPEUTIC PHARMACEUTICAL AGENT FOR HIV INFECTIOUS DISEASES CHARACTERIZED BY COMPRISING COMBINATION OF INTEGRASE INHIBITOR AND ANTI-HIV AGENT | SHIONOGI & CO., LTD. (JP) | 2023-02-23 | — | — | US | disclosed |
| EP-4066839-A1 | PROPHYLACTIC AND THERAPEUTIC PHARMACEUTICAL AGENT FOR HIV INFECTIOUS DISEASES CHARACTERIZED BY COMPRISING COMBINATION OF INTEGRASE INHIBITOR AND ANTI-HIV AGENT | Shionogi & Co., Ltd (JP) | 2022-10-05 | — | — | EP | disclosed |
| US-20210186992-A1 | METHOD AND COMPOSITIONS FOR THE TREATMENT OF ANEMIA THROUGH THE INHIBITION OF FURIN | BRIGHAM YOUNG UNIVERSITY | 2021-06-24 | — | — | US | disclosed |
| WO-2021107066-A1 | PROPHYLACTIC AND THERAPEUTIC PHARMACEUTICAL AGENT FOR HIV INFECTIOUS DISEASES CHARACTERIZED BY COMPRISING COMBINATION OF INTEGRASE INHIBITOR AND ANTI-HIV AGENT | 塩野義製薬株式会社 | 2021-06-03 | — | — | WO | disclosed |
| US-20210052621-A1 | METHODS FOR TREATING FLAVIVIRUSES AND ZIKA INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION (US) | 2021-02-25 | — | — | US | disclosed |
| US-20180221406-A1 | THERAPEUTIC COMBINATIONS OF ANTIVIRAL AND ANTI-INFLAMMATORY THERAPIES | FORESIGHT BIOTHERAPEUTICS, INC. (US) | 2018-08-09 | — | — | US | disclosed |
| US-20170296601-A1 | Compositions and Methods for Treating an Immunodeficiency Virus Infection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-10-19 | — | — | US | disclosed |
| CN-100424095-C | Recombinant targeted toxin against HIV-1 | MILITARY VETERINARY INST QUART (CN) | 2008-10-08 | — | — | CN | disclosed |
| CN-1621418-A | Recombinant targeted toxin against HIV-1 | MILITARY VETERINARY INST QUART (CN) | 2005-06-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180221406-A1 | THERAPEUTIC COMBINATIONS OF ANTIVIRAL AND ANTI-INFLAMMATORY THERAPIES | EIF2AK2, IRF3, IFNG | CYP3A4 825/4885ABCC3 2843/4885ABCB11 3192/4885 |
| US-20240041828-A1 | Combination Therapeutics Comprising Nrf2 Agonists and Antivirals for Treating Viral Infections | KEAP1, HMOX1, NFE2L2 | CYP3A4 785/4885ABCC3 1334/4885ABCB11 4192/4885 |
| US-12564595-B2 | Prophylactic and therapeutic pharmaceutical agent for HIV infectious diseases characterized by comprising combination of integrase inhibitor and anti-HIV agent | RPL35, RPL7, TYMP | CYP3A4 309/4885ABCC3 775/4885ABCB11 441/4885 |
| US-12083099-B2 | Methods of treating symptoms of coronavirus infection with viral protease inhibitors | ACE, ACE2, TMPRSS2 | CYP3A4 1061/4885ABCC3 4542/4885ABCB11 4654/4885 |
| US-20230113114-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION WITH VIRAL PROTEASE INHIBITORS | ACE, ACE2, TMPRSS2 | CYP3A4 1061/4885ABCC3 4542/4885ABCB11 4654/4885 |
| US-20230059640-A1 | PROPHYLACTIC AND THERAPEUTIC PHARMACEUTICAL AGENT FOR HIV INFECTIOUS DISEASES CHARACTERIZED BY COMPRISING COMBINATION OF INTEGRASE INHIBITOR AND ANTI-HIV AGENT | NHERF1, INO80C, IMPA1 | CYP3A4 737/4885ABCC3 75/4885ABCB11 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.